Jan Alan Alfheim

Chief Executive Officer


Jan A. Alfheim is a business executive with over thirty years of experience bringing product ideas and technology to the chemical and pharmaceutical markets, from product concept inception through discovery and development phases to final marketing campaign and launch. He has direct experience in research, project management, business development & partnering, company start-ups, and product launches. Alfheim comes from Nordic Nanovector ASA where he was Chief Executive Officer from 2011 until 2014 and Chief Operating Officer from 2014 to 2016. Prior to working at Nordic Nanovector, he has held senior roles of increasing importance including Chief Business Officer at Clavis Pharma, President of StemPath Inc, Director of Business Development at Neurochem Inc and Project Director at Nycomed Imaging. Jan A. Alfheim holds a MBA from the University of McGill and a MSc from Concordia University.

Tina Bjørnlund Bønsdorff

Chief Scientific Officer


Dr. Tina B. Bønsdorff has more than 15 years of experience in molecular biology. She has Ph.D. and postdoctoral experience from the Norwegian School of Veterinary Science, where she worked in the field of gene identification, expression and mutation analysis. Her postdoctoral research was focused on gene expression analysis of early neoplastic lesions in dog with inherited cancer syndromes. Dr. Bønsdorff is one of the founders of Oncoinvent AS (2010). Dr. Bønsdorff was the Chief Scientific Officer of Oncoinvent AS from the start-up until August 2013, and the CEO of the company from August 2013 to September 2016.

Øyvind Sverre Bruland

Chief Medical Officer


Dr. Øyvind S. Bruland is a MD, Ph.D. and professor of Clinical Oncology, Faculty of Medicine, University of Oslo and senior consultant oncologist at Dept. of Oncology, Oslo University Hospital. Professor Bruland founded Algeta ASA in 1997 together with Dr. Roy H. Larsen, and he was one of the founders of Nordic Nanovector ASA (2009) and of Oncoinvent AS (2010). Øyvind S. Bruland was a member of the board of Oncoinvent AS from 2010 to 2016. Professor Bruland has supervised a high number of Ph.D. students, and his main clinical experience and research has been devoted to primary bone and soft tissue cancers (sarcomas).

Ole Peter Nordby

Chief Financial Officer


Ole P. Nordby holds a MBA from the Norwegian Business School BI and is a Certified European Financial Analyst (CEFA). He also earned a degree as Master of Theology and has completed additional courses in molecular biology at the University of Oslo. Nordby has acquired a deep knowledge of the Norwegian financial market after serving for more than 15 years in positions as portfolio manager, investment director and financial analyst at several funds and investment companies. Through the main part of his career as fund manager and analyst he has been occupied with listed Nordic companies in the Life Science sector. Since late 2013 Nordby has had the opportunity to achieve additional experience as co-founder of two research-based early-stage companies and from positions as Board member in companies in the Life Science and Financial industries.